Loss of chromosome 1p may have a prognostic value in localised Neuroblastoma: results of the French NBL 90 study

Delattre, Olivier; Hartmann, Olivier; Combaret, Valérie; Michon, Jean; Bénard, Jean; Peyroulet, M C; Plantaz, Dominique; Coze, Carole; Chastagner, Pascal; Baranzelli, M. C.; Frappaz, Didier; Lemerle, J; Santini, Daniele

doi:10.1016/s0959-8049(97)00295-5

Cited by 31 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Between March 1990 and September 1999, all cases of localized neuroblastoma treated at 31 centers of The French Society of Pediatric Oncology (SFOP) were included in two consecutive prospective multicenter studies. In the first study (NBL90) [7][8][9][10], patients with localized NB were treated by primary surgery if complete gross resection was considered as feasible without mortality or major functional morbidity but no specific criteria of resectability were used to select patients. Overall in the first study (i.e.…”

Section: Introductionmentioning

confidence: 99%

Localized cervical neuroblastoma: prevention of surgical complications

Haddad¹,

Triglia²,

Helardot³

et al. 2003

International Journal of Pediatric Otorhinolaryngology

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Localized cervical neuroblastoma: prevention of surgical complications

Haddad¹,

Triglia²,

Helardot³

et al. 2003

International Journal of Pediatric Otorhinolaryngology

Self Cite

View full text Add to dashboard Cite

“…Genetic abnormalities at chromosome 1p (Rubie et al, 1997a), 3p, 11q (Spitz et al, 2003;Attiyeh et al, 2005;Simon et al, 2006) and 17q (Brinkschmidt et al, 2001), as well as biochemical (Simon et al, 2003), histological (Perez et al, 2000;Navarro et al, 2006;Sano et al, 2006), and biological factors (Christiansen et al, 1995;Cheung et al, 1997;Kramer et al, 1997;Perez et al, 2000;Ladenstein et al, 2001;Mora et al, 2001;Krams et al, 2003;Riley et al, 2004;Haber et al, 2006;Spitz et al, 2006), do not seem to have the same relevance in patients with localised NB as they do in patients with metastatic disease. Gene expression profiling and GCH studies have suggested specific favourable and unfavourable NB signatures (Takita et al, 2004;Ohira et al, 2005;Vandesompele et al, 2005), but presently a widespread identification of patients at risk of relapse by these techniques cannot be envisaged.…”

mentioning

confidence: 99%

Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma

et al. 2008

View full text Add to dashboard Cite

The impact of bone marrow (BM) GD2-positive cells on survival has been evaluated in 145 Italian children with localised neuroblastoma (NB) evaluated at diagnosis by anti-GD2 immunocytochemistry. Nineteen of these (13.1%) were found to be BM GD2-positive, with the number of positive cells ranging between 1 and 155 out of 1 Â 10 6 total cells analysed. Seven/19 (38.8%) GD2-positive vs 12/126 (9.5%) GD2-negative patients relapsed. The 5-year event-free survival (EFS) and overall survival of the GD2-positive patients was significantly worse than that of the GD2-negative ones (62.2 vs 89.9%, Po0.001; and 74.9 vs 95.9%, P ¼ 0.005, respectively). GD2 positivity was not associated to other known risk factors, and in particular to Myc-N amplification and 1p deletion. Among Myc-N-negative patients, the EFS of those negative for both GD2 and 1p deletion was significantly better than in children positive for either one of these two markers (EFS ¼ 96.9 vs 66.0%, Po0.001). In conclusion, GD2 positivity may represent a prognostic marker for patients with non-metastatic NB without Myc-N amplification, and its combination with genetic alterations might help identifying patients that require a more careful follow-up.

show abstract

“…There has been ongoing controversy about the precise prognostic power of 1p deletion in relation to other variables, particularly MYCN [15,40]. Some studies showed that an inverse relationship exists between 11q loss and amplification of MYCN, indicating that these abnormalities represent distinct genetic subtypes of advanced-stage NB [38]; multiple studies found a significant association between 11q, 3p, and 14q loss [49][50][51].…”

Section: Discussionmentioning

confidence: 99%

Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma

et al. 2008

View full text Add to dashboard Cite

Neuroblastoma (NB) is a pediatric neoplasia that shows complex combinations of acquired genetic aberrations. The specific genes and the molecular mechanisms responsible for development and progression of NB remain poorly understood. Our main objective is to compare the results obtained with different techniques for the detection of genomic data in 20 patients with NB using the information obtained to select the appropriate technique in routine analysis for the therapeutic stratification. The genetic methods used in this study are multiprobe fluorescence in situ hybridization (FISH) assay, metaphasic comparative genomic hybridization (mCGH), array comparative genomic hybridization (aCGH), and the multiplex ligation-dependent probe amplification (MLPA). Genomic copy number abnormalities were used to group the cases in four categories: MYCN amplification cases; 11q deletion tumors; cases with partial chromosome gains or losses and samples with entire chromosome alterations. The data obtained from the multigenomic techniques showed a high degree of concordance and our findings support the hypothesis that NB consists of biologically distinct subgroups that differ by genetic characteristics of prognostic relevance. FISH will be essential for the mandatory study of MYCN status. The use of MLPA as routine technique is an advantage procedure for detecting the implication of the common genetic alterations in NB.

show abstract

Loss of chromosome 1p may have a prognostic value in localised Neuroblastoma: results of the French NBL 90 study

Cited by 31 publications

References 23 publications

Localized cervical neuroblastoma: prevention of surgical complications

Localized cervical neuroblastoma: prevention of surgical complications

Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma

Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma

Contact Info

Product

Resources

About